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Pconomic Effects of Prolonged Clopidogrel
herapy After Percutaneous Coronary Intervention
atricia A. Cowper, PHD,*† Krishna Udayakumar, MD, MBA,† Michael H. Sketch, JR, MD,†
ric D. Peterson, MD, MPH, FACC*†
urham, North Carolina
OBJECTIVES This study examined the incremental cost-effectiveness of extending clopidogrel therapy from
one month to one year after percutaneous coronary intervention (PCI) in an unselected,
heterogeneous patient population.
BACKGROUND Clinical trials suggest that prolonging clopidogrel therapy for up to one year after PCI reduces
downstream cardiac events. However, clopidogrel therapy is costly and may increase bleeding
risk.
METHODS Using decision analysis, we compared the outcomes and cost of prolonging clopidogrel
treatment from one month to one year after PCI with the alternative strategy of discontinuing
therapy one month after the procedure. Event rates were based on 3,976 PCI patients who
were treated between January 1999 and December 2001 at the Duke Medical Center and
received no more than one month of clopidogrel after the procedure. Baseline characteristics
and event rates were obtained from Duke clinical information systems. The effect of
prolonged clopidogrel therapy on event rates was based on the Clopidogrel for the Reduction
of Events During Observation (CREDO) trial per-protocol data. Unit costs and the effect of
myocardial infarction (MI) on life expectancy were based on published sources.
RESULTS Extending clopidogrel therapy from one month to one year after PCI cost $879 per patient
and reduced the risk of MI by 2.6%. Assuming MI decreases life expectancy by two years,
prolonged therapy would cost $15,696 per year of life saved. Economic attractiveness of
therapy varied with baseline risk, the effect of prolonged therapy on MI risk, and the price of
clopidogrel.
CONCLUSIONS Prolonging clopidogrel therapy for one year after PCI is economically attractive, particularly
in high-risk patients. (J Am Coll Cardiol 2005;45:369–76) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.041College of Cardiology Foundation
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over 500,000 percutaneous coronary interventions (PCIs)
ith stent implantation are performed annually in the U.S.
1). In these patients, the combination oral antiplatelet
herapy of aspirin and clopidogrel for one month after PCI
educes thrombotic complications relative to aspirin therapy
lone (2,3). However, there remains considerable debate as
o how long clopidogrel therapy should be maintained (4,5).
Although two recent trials suggest that prolonging ther-
py for up to one year after PCI reduces downstream cardiac
vents, patients treated with clopidogrel may have an
ncreased risk of bleeds (8.8% vs. 6.7%, p  0.07) (6,7). In
ddition, clopidogrel therapy is costly ($100 per month).
o date, there have been no published analyses of the
ncremental cost-effectiveness of prolonged clopidogrel
reatment after PCI (one month to one year) versus the
revious standard of one month of therapy. In this study, we
ssessed the value of prolonged clopidogrel therapy in an
nselected, heterogeneous population of patients treated in
he era of bare-metal stents. First, we determined the rate of
From the *Outcomes Research and Assessment Group, Duke Clinical Research
nstitute, and †Duke University Medical Center, Durham, North Carolina. Financial
upport for this study was provided by grant U18HS10548 (Duke Center for
ducation and Research on Therapeutics) from the Agency for Healthcare Research
nd Quality, U.S. Department of Health and Human Services, Rockville, Maryland.
ric Peterson has an unrestricted educational research grant for a separate study of
cute coronary syndrome from BMS Sanofi, Plainsboro, New Jersey.s
Manuscript received June 28, 2004; revised manuscript received October 17, 2004,
ccepted October 18, 2004.ardiac events during the year after PCI among patients
eceiving one month of treatment. We then examined the
ncremental benefits and cost-effectiveness of extending
lopidogrel therapy from one month to one year after PCI
n this population. Finally, we explored the effect of patient
isk on the cost-effectiveness of prolonged clopidogrel therapy.
ETHODS
atient population. The study sample included patients
ndergoing PCI at Duke University Medical Center be-
ween January 1, 1999, and December 31, 2001. During this
ime, which corresponds to the study periods of the two
ajor clopidogrel trials, the standard of care at Duke was to
reat patients with one month of clopidogrel after bare-
etal stent implantation (6,7). Patients were included in the
ample if they: 1) were over 21 years of age; 2) did not have
ignificant left main coronary artery disease; 3) did not
ndergo percutaneous revascularization in the two weeks
efore the index PCI; 4) did not have a “staged procedure”
two planned procedures in the same admission); 5) did not
eceive intracoronary radiation therapy for in-stent resteno-
is; and 5) were treated with no more than one month of
lopidogrel after the procedure.
odel. A decision model was developed to compare the
utcomes and costs of prolonging clopidogrel therapy from
ne month to one year after PCI with the alternative
trategy of discontinuing therapy after one month of
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Economic Effects of Prolonged Clopidogrel Therapy February 1, 2005:369–76eriprocedural clopidogrel (DATA 3.5; TreeAge Software
nc., Williamstown, Massachusetts) (Fig. 1). In each treat-
ent arm, the model included myocardial infarction (MI),
evascularization (coronary artery bypass grafting [CABG]
s. PCI), major bleeding, and death (Fig. 1). Events that
ere rare or had minimal economic consequences (e.g.,
troke, minor bleeds) were excluded, as their effect on results
as negligible.
The analysis was conducted from the perspective of
ociety (8,9). Primary outcomes included the incremental
ost and the incremental cost per MI prevented with
lopidogrel therapy between one and 12 months after the
ndex PCI. Using secondary data sources, we also extrapo-
ated beyond the trial period to estimate the incremental
ost per year of life saved associated with prolonging
lopidogrel therapy from one month to one year after PCI.
ata sources. BASELINE CHARACTERISTICS AND EVENT
ATES. Baseline demographics, clinical characteristics,
reatments, discharge medications, and rates of major events
MI, death, repeat revascularization) after PCI (given one
onth of therapy) were obtained from the Duke Informa-
ion System for Cardiovascular Care (DISCC). The
ISCC events are obtained through annual mail and
elephone follow-up of patients, supplemented by searches
f Duke claims data and the National Death Index. The
Is were confirmed by discharge summaries. The DISCC
ollow-up was 96% complete in our time frame. Conditional
vent rates were derived as needed (probability of revascu-
arization conditional on MI; probability of CABG condi-
ional on revascularization and MI; probability of death
onditional on MI and revascularization). Rates of major
leeding were based on Clopidogrel for the Reduction of
vents During Observation (CREDO) trial data for per-
rotocol patients (those who underwent percutaneous re-
ascularization), because bleeding complications are not
ystematically recorded in DISCC (Dr. S. Steinhubl, per-
onal communication, June 20, 2003).
The effect of prolonged clopidogrel therapy on rates of MI
relative risk 0.56), major bleeding (relative risk 1.46), repeat
evascularization (relative risk 1.0), and death (relative risk 1.0)
uring the 1- to 12-month follow-up period was based on
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CREDO  Clopidogrel for the Reduction of Events
During Observation trial
DISCC  Duke Information System for
Cardiovascular Care
DRG  diagnosis-related group
EPILOG  Evaluation in PTCA to Improve Long-term
Outcome with abciximab GP IIb/IIIa
blockade trial
GP  glycoprotein
MI  myocardial infarction
PCI  percutaneous coronary interventionREDO per-protocol data (Dr. S. Steinhubl, personal com-unication, June 20, 2003). The relative risk reduction asso-
iated with clopidogrel treatment was assumed to be constant
cross all patient subgroups, as was found in CREDO (6).
NIT COSTS. Hospitalization costs were based on average
edicare reimbursement for diagnosis-related group
DRG) categories for major clinical events and event com-
inations in the decision model (MI with/without death,
CI with/without MI, gastrointestinal bleed, cardiac arrest)
nd on average Medicare payments for CABG procedures
Table 1) (10,11). The incremental cost of death (in
ddition to events other than MI and CABG) was based on
he difference in DRG payments for MI with and without
eath. An estimate of the incremental cost of bleeds was
btained from the Evaluation in PTCA to Improve Long-
erm Outcome with abciximab GP IIb/IIIa blockade
EPILOG) economic substudy (12). Physician fees were
alculated using Medicare fee schedules for procedures and
npatient management, assuming average lengths of stay
eported for DRGs (10,13). The cost of clopidogrel was
ased on the average wholesale price plus a monthly
ispensing fee (14). Costs were adjusted to $2,000 (U.S.)
sing the average annual Producer Price Index for general
edical and surgical hospitals (15).
IFE EXPECTANCY. Estimates of life expectancy were based
n two previous analyses of longitudinal data. Age- and
ender-specific estimated life expectancies for patients with
history of coronary heart disease were obtained from an
nalysis of Framingham Heart Study data and applied to the
uke sample to obtain overall life expectancy for the model
16). The post-acute reduction in this life expectancy
ssociated with a nonfatal MI was obtained from previous
nalyses of longitudinal DISCC data (17). Alternative
stimates of the reduction in life expectancy attributable to
I were examined in sensitivity analyses.
nalysis. The baseline analysis was based on event rates in
he Duke sample and incorporated assumptions in Table 1.
he expected cost and event rates for the period between
ne month and one year after PCI were compared between
reatment strategies. The incremental cost per MI avoided
ith prolonged therapy was then calculated for the 11-
onth follow-up period. The denominator in this ratio
eflects only the clinical consequences of MI, because any
osts associated with MI are included in the numerator. The
ost per year of life saved over a patient’s lifetime with
rolonged therapy was also calculated using the external
stimates of the effect of MI on life expectancy described
arlier. In the analysis, years of life gained in the future were
iscounted at the standard annual rate of 3% (18).
Single and multiway sensitivity analyses were performed
o assess the robustness of results to reasonable variations in
linical and economic factors. Variables examined included
he relative risk reduction for MI, cost of MI, rate and cost
f major bleeds, price of clopidogrel, medication compli-
nce, and reduction in life expectancy due to MI.The analyses were repeated for high- and low-risk patient
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February 1, 2005:369–76 Economic Effects of Prolonged Clopidogrel Therapyubgroups to determine the extent to which the economic
ttractiveness of long-term clopidogrel varies with patient
haracteristics. First, we identified clinical factors associated
ith higher rates of MI in follow-up using a logistic
egression model. A high-risk subgroup was then empiri-
ally defined as patients having diabetes, multivessel inter-
ention, or MI within 24 h preceding their procedure.
atients not classified as higher risk comprised the lower
isk subgroup.
ESULTS
atient characteristics. A total of 4,037 Duke patients met
he inclusion criteria and were included in the Duke PCI
ample. Study patients were similar in age to patients
nrolled in CREDO (Table 2) (6). However, Duke patients
ere more likely to be female and non-white and have
iabetes, a history of MI, and a recent MI as the indication
igure 1. Decision model subtree for no clopidogrel arm. A parallel subtre
odes. Revasc  revascularization.or their index PCI. In addition, the use of glycoprotein iGP) IIb/IIIa inhibitors was almost twice as common in the
uke sample.
vent rates. Of the total Duke sample, 3,976 Duke pa-
ients (98%) were alive one month after their index PCI and
ere included in the analyses. Among Duke patients sur-
iving at least one month, the rates of MI and death in the
ubsequent 11 months were considerably higher than those
n CREDO (Table 3). Compared with CREDO, the death
ate among Duke patients was three times as high (4.2% vs.
.4%) and the MI rate was almost twice as high (5.8% vs.
.2%). Among high-risk patients, death and MI rates
eached 5.1% and 8%, respectively. Even the lower risk
atients treated at Duke had higher event rates than those
bserved in CREDO (death: 3.4% vs. 1.4%; MI: 3.7% vs.
.2%).
Patients with MI had a greater risk of experiencing
dditional events relative to other patients. Of events
xplicitly included in the model, MI patients were at
s for the treatment arm. Circles  chance nodes; arrowheads  terminalncreased risk of revascularization (60% vs. 11.5%), CABG
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Economic Effects of Prolonged Clopidogrel Therapy February 1, 2005:369–76if revascularized) (29.7% vs. 26.7%), and death (11.6% vs.
.6% if revascularized; 14.0% vs. 3.9% if not revascularized).
ffect of MI on expected survival. Based on age- and
ender-specific life expectancies for Framingham heart dis-
ase patients, the expected survival of patients in the Duke
ample was 13.2 years (undiscounted). The estimated re-
uction in life expectancy of patients surviving six months
fter acute MI was approximately two years (undiscounted)
17). Combining these estimates gave an estimated life
xpectancy for patients surviving an MI of 11.2 years
undiscounted).
able 1. Unit Costs*
Variable Amount
ospitalization cost
CABG $26,918
PCI (no MI/MI) $9,035/$11,309
MI (no death/death) $5,580/$6,440
Death (no other event) $4,465
Bleed (no other event) $4,127
Incremental cost of death $2,011
Incremental cost of major bleed $3,592
hysician fees
CABG admission (/ MI, death) $3,637–$4,427
MI admission (no death/death) $502/$798
PCI admission (/ MI, death) $1,471–$2,058
Major bleed admission (no death/death) $480/$815
Death only $463
Incremental fee for bleed admission $123
lopidogrel cost $3.22/day  $2.50/
month dispensing fee
Costs in year 2000 U.S. dollars.
/  with or without; CABG  coronary artery bypass graft surgery; MI 
yocardial infarction; PCI  percutaneous coronary intervention.
able 2. Baseline Patient Characteristics
Duke Sample
(n  4,037)
CREDO
(n  2,116)
ge (yrs) 62  12 62  11
ender (% female) 35 29
ace (% non-white) 26 11
isk factors (%)
Previous MI 52 34
Previous stroke 5 7
Diabetes 29 26
Peripheral vascular disease 10 10
Hyperlipidemia 60 75
Smoking (past year) 24 31
ndication for PCI (%)
Recent MI 30 14
Unstable/worsening angina* 55 53
Other 15 33
rocedural characteristics†
Stent(s) used (%) 92 89
Number of stents 1.6  0.9 1.5  0.8
GP IIb/IIIa inhibitor use (%) 86 45
In Duke sample, defined as unstable or worsening; in CREDO, defined as unstable.
Per-protocol CREDO population. Data are presented as the mean  SD or
ercentage of patients.p
CREDO  Clopidogrel for the Reduction of Events During Observation; GP 
lycoprotein; MI  myocardial infarction; PCI  percutaneous coronary intervention.aseline analysis: total sample. Extending clopidogrel
herapy from one month after PCI to one year after the
rocedure reduced inpatient costs by $236 due to the
ecreased incidence of MI (5.8% to 3.2%). These savings
ere more than offset by the additional cost of clopidogrel
$1,115), resulting in a net increase in total cost of $879 per
atient (Table 4). Thus, the estimated cost of prolonged
lopidogrel therapy per MI avoided between one month and
ne year after PCI was $34,336. Assuming life expectancy is
educed by about two years per MI (before discounting), the
ost-effectiveness of continuing clopidogrel between one
onth and one year would be $15,696 per year of life saved
Table 4).
aseline analysis: high- and low-risk subsets. In the high-
isk subset, the incremental cost of prolonging clopidogrel
herapy from one to 12 months after PCI was slightly lower
han that in the total sample ($775 vs. $879) (Table 5).
his, combined with a larger absolute reduction in the
ncidence of MI in the high-risk subgroup (8% to 4.5%),
aused clopidogrel to have a lower incremental cost per MI
voided ($21,893). This translated into a cost-effectiveness
atio of $10,333 per year of life saved for high-risk patients.
Prolonged clopidogrel therapy was less economically
ttractive among patients lacking high-risk features (Table
). The lower incidence of MI in this subgroup (3.7%)
esulted in smaller absolute reductions in MIs (1.6%) and
ssociated inpatient costs ($132) per patient. The cost-
ffectiveness ratios were almost triple those for the high-risk
ubset ($59,939 per MI avoided and $26,568 per year of life
aved).
ensitivity analyses. RELATIVE RISK OF MI. The economic
ttractiveness of clopidogrel therapy was relatively robust to
oderate reductions in the effect of clopidogrel on the rate
f MI. An absolute increase of 10% in the relative risk for
I with clopidogrel from the baseline value of 0.56 would
ot change the cost-effectiveness substantially (Fig. 2).
owever, if the relative risk for MI associated with long-
erm clopidogrel therapy increased above 85%, which is
ithin the confidence interval of the estimate (0.3–1.0), the
ost-effectiveness ratio would increase sharply and exceed
50,000 for the total sample.
EDICATION COST AND COMPLIANCE WITH THERAPY. The
conomic attractiveness of the clopidogrel strategy was
ensitive to variation in the price of the drug (Fig. 3). A
ecrease of one-third in the price of clopidogrel from $3.22
o $2.15 daily would reduce the incremental cost of the
lopidogrel strategy by $361 (from $879 to $518), resulting
n a cost per year of life saved of only $9,250. In the
igh-risk subset, a 33% price reduction would result in a
ost per year of life saved of $5,520 (Fig. 3).
Compliance with therapy in CREDO was fairly low in
oth the treatment and control groups (63% and 61%,
espectively). If all patients were compliant with drug
herapy and the effectiveness of clopidogrel increased in
roportion to the improvement in compliance (improving
t
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February 1, 2005:369–76 Economic Effects of Prolonged Clopidogrel Therapyhe relative risk of MI from 0.56 to 0.42), the cost per year
f life saved would improve to $10,622 (incremental cost of
786; years of life saved of 0.074).
OST OF MI. As the cost of hospitalization for MI in-
reased, the financial attractiveness of clopidogrel therapy
mproved because savings from avoided hospitalizations
ncreased. Due to the low frequency of MIs, relatively large
hanges in the cost of MI had only a moderate effect on the
xpected cost and cost-effectiveness of the clopidogrel strat-
gy. For example, in the total sample, even if the inpatient
osts associated with MI tripled, the cost per patient of
xtended clopidogrel therapy would still exceed the no
reatment strategy by $713, leaving a cost-effectiveness ratio
f $12,732 per year of life saved.
OST AND RELATIVE RISK OF MAJOR BLEEDS. Results were
elatively insensitive to variations in the effect of clopidogrel
n the incidence of major bleeds and in the cost of bleeds,
ue to the low baseline risk of major bleeding (3%). Even if
he cost of treating major bleeds increased by 30% and the
elative risk for major bleeding increased from 1.4 to 2, the
ost per year of life saved in the total sample would increase
o only $17,589. Similarly, the cost-effectiveness would
mprove only marginally from $15,696 to $14,589 per year
f life saved if excess bleeds with clopidogrel were
liminated.
Table 3. Event Rates Between One and 12 M
Patient
Population
Sample
Size
No Clop
Death MI
CREDO 910 1.4 3.2
Duke
Total 3,976 4.2 5.8
High risk 1,919 5.1 8.0
Low risk 2,057 3.4 3.7
*Assumes relative risk for MI with clopidogrel treatment from
rate in model.
CREDO  Clopidogrel for the Reduction of Events D
revascularization.
Table 4. Modeled Outcomes and Cost-Effectiv
Variable Clopidogr
Cost*
Hospital $2,252
Physician $317
Medications $1,115
Total $3,715
Outcomes
Death (1 month to 1 yr) 3.92%
MI (1 month to 1 yr) 3.24%
Life expectancy (discounted yrs)† 10.43
Cost-effectiveness
$/MI avoided
$/yr of life saved*Between 1 and 12 months following after percutaneous coronary
MI  myocardial infarction.EDUCTION IN LIFE EXPECTANCY DUE TO MI. There is
onsiderable uncertainty regarding the effect of MI on life
xpectancy. If the baseline estimate of years of life lost over
lifetime due to an MI (two years) were reduced by 50%,
he cost-effectiveness ratio for the total sample would
ncrease from $15,696 to $21,975. Similar reductions in the
ffect of MI on long-term survival would increase the cost
er year of life saved to $14,706 for high-risk patients and
ver $36,000 in the low-risk subgroup (Fig. 4).
ISCUSSION
lthough there is growing evidence supporting the effec-
iveness of prolonged clopidogrel therapy, some clinicians
ave expressed concern about its broad application, given
he cost of treatment (4). Our study suggests that continu-
ng clopidogrel therapy after PCI beyond one month and
ut to at least one year in a tertiary care practice setting is
conomically attractive relative to currently accepted treat-
ents (19). The value of prolonged therapy varies with
atient characteristics and is greatest for patients at high risk
f MI. The cost-effectiveness of prolonged therapy is similar
o that estimated for statin therapy in secondary prevention
20,21).
mportance of relative risk for MI with clopidogrel. Our
esults hinge on the ability of clopidogrel to reduce the
After Percutaneous Coronary Intervention
el (%) Clopidogrel (%)
vasc
Major
Bleed MI*
Absolute Risk
Reduction (MI)*
5.2 3.0 1.8 1.4
4.3 n/a† 3.2 2.6
6.5 n/a† 4.5 3.5
2.3 n/a† 2.1 1.6
DO (0.56). †Not available for Duke sample; used CREDO
Observation trial; MI  myocardial infarction; Revasc 
s: Total Sample
No Clopidogrel
Difference
(Clopidogrel vs. None)
$2,459 $207
$346 $29
$0 $1,115
$2,819 $896
4.15% 0.23%
5.80% 2.56%
10.37 0.056
$34,336
$15,696onths
idogr
Re
1
1
1
1
CREenes
elintervention. †Years of life discounted at 3% per year.
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Economic Effects of Prolonged Clopidogrel Therapy February 1, 2005:369–76ncidence of MI beyond one month after PCI. Fewer MIs
esult in savings from less frequent hospitalizations and
onger expected survival. A moderate reduction in the
ffectiveness of clopidogrel in preventing MIs would not
ffect the results substantially. However, if the relative risk
or MI with clopidogrel rose above 0.85 (from 0.56), which
s within the confidence interval for the estimate (0.3 to
.0), the cost per year of life saved with prolonged therapy
ould become much less attractive and would be prohibitive
n the low-risk group. Because high-risk patients have an
ncreased risk of MI, clopidogrel therapy is most econom-
cally attractive in this group.
ensitivity of results to other factors. The cost-effectiveness
f therapy was directly related to the price of clopidogrel.
lthough this analysis was conducted from a societal per-
pective, it is worth noting that without comprehensive
rescription drug coverage, the financial burden of clopi-
able 5. Modeled Outcomes and Cost-Effectiveness: High- and
Variable
High-Risk Su
Clopidogrel
No
Clopidogre
ost*
Hospital $2,602 $2,900
Physician $365 $407
Clopidogrel $1,115 0
Total $4,082 $3,307
utcomes
Death (1 month to 1 yr) 4.72% 5.01%
MI (1 month to 1 yr) 4.46% 8.0%
Life expectancy (discounted yrs)† 10.33 10.26
ost-effectiveness
$/MI avoided $21,893
$/yr of life saved $10,333
Between 1 and 12 months after percutaneous coronary intervention. †Years of life d
MI  myocardial infarction.
igure 2. Cost-effectiveness of prolonged clopidogrel therapy: sensitivity to
ariation in relative risk for myocardial infarction (MI). The cost per year
f life saved is shown for values of relative risk for MI between 0 and 1.
olid line without symbols all patients; line with triangles high-risk
atients; line with circles  low-risk patients. Baseline value of relative
isk for MI is indicated by the vertical dotted line.

bogrel therapy would fall primarily on patients. The addi-
ional burden may be particularly problematic in this pop-
lation of patients, which is typically prescribed multiple
ong-term medications for heart disease, costing several
undred dollars per month. Third-party coverage of outpa-
ient medications or a decrease in medication cost would
educe the burden to patients and improve the cost-
ffectiveness of prolonged therapy considerably. In the
bsence of coverage, physicians and patients may have to
ontemplate the value of clopidogrel relative to other med-
cations currently prescribed, in light of each patient’s
pecific risk profile.
Results were relatively robust to variation in the estimate
f the effect of MI on life expectancy, but prolonged
lopidogrel therapy became increasingly less attractive as the
urvival advantage gained by avoiding an MI fell below one
ear. Variation in the cost of MI, cost of bleeds, and effect
Risk Subsets
Low-Risk Subset
Difference
(Clopidogrel
vs. None) Clopidogrel
No
Clopidogrel
Difference
(Clopidogrel
vs. None)
$298 $1,925 $2,040 $115
$42 $271 $288 $17
$1,115 $1,115 0 $1,115
$775 $3,311 $2,328 $983
0.29% 3.21% 3.37% 0.16%
3.54% 2.06% 3.70% 1.64%
0.075 10.53 10.49 .037
$59,939
$26,568
ted at 3% per year.
igure 3. Cost-effectiveness of prolonged clopidogrel therapy: sensitivity to
ariation in price of clopidogrel. The cost per year of life saved is shown for
lopidogrel prices between $0 and $4 per day. Solid line without symbols
all patients; line with triangles  high-risk patients; line with circlesLow-
bset
llow-risk patients. Baseline value for daily price of clopidogrel is indicated
y the vertical dotted line.
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February 1, 2005:369–76 Economic Effects of Prolonged Clopidogrel Therapyf clopidogrel on bleeding had relatively little impact on the
ost-effectiveness of prolonged therapy.
tudy sample compared with CREDO population.
vent rates in our observational sample were considerably
igher than those found in CREDO. This difference
eflects the greater baseline risk in study patients relative to
he CREDO population and is consistent with literature
uggesting that patients treated in the community have a
ess favorable risk profile than those enrolled in randomized
rials (22,23). Assuming the relative effectiveness of clopi-
ogrel does not vary with patient risk, the greater baseline
isk in the community increases the potential absolute
enefit of prolonged clopidogrel treatment. The study
ample also differed from the CREDO population in terms
f GP IIb/IIIa inhibitor usage, with study patients being
reated almost twice as often as CREDO patients. This
ifference is unlikely to have affected the results, because the
tudy period did not include the first month after the
rocedure, during which time the benefits of GP IIb/IIIa
nhibitors are realized (24).
omparison with the CURE analysis. Although our
tudy suggests that prolonging clopidogrel therapy may be
orthwhile, particularly in high-risk patients, our results are
onsiderably less favorable than the estimated cost per year
f life saved of 1,365€ (approximately $1,650) in a recent
ost-effectiveness analysis of CURE (25). Unlike our study,
he CURE analysis combined the effects of initial therapy
one month of clopidogrel) with prolonged treatment. This
pproach overestimates the value of prolonged therapy,
ecause treatment in the periprocedural period is more
ffective than in the subsequent months and costs a fraction
f the expense associated with extended therapy. As in our
tudy, the CURE analysis found that results were sensitive
o the effectiveness of clopidogrel in preventing events and
igure 4. Cost-effectiveness of prolonged clopidogrel therapy: sensitivity to
ariation in estimate of the reduction in life expectancy associated with
yocardial infarction (MI). The cost per year of life saved is shown for a
ange of values of reduction in life expectancy subsequent to MI. Solid line
ithout symbols  all patients; line with triangles  high-risk patients;
ine with circles  low-risk patients. Baseline value for reduction in life
xpectancy due to MI is indicated by the vertical dotted line.nsensitive to the cost of bleeds. ttudy limitations. There are several limitations to this
tudy. First, the model was based on one year of data, and
ifetime survival was extrapolated using available external
stimates. Although these extrapolations are somewhat
mprecise, they offer insight regarding the potential benefits
f preventing downstream events and provide a metric with
hich to compare the treatment’s value with that of other
ealth care interventions. In this regard, contemporary
ong-term follow-up data are needed to better determine the
urvival benefits associated with preventing nonfatal MI.
econd, this study addressed the issue of prolonging therapy
ntil one year after the procedure. Unfortunately, the extent
o which the relative benefits of clopidogrel continue to
ccrue beyond one year is unknown, limiting our ability to
stimate the cost-effectiveness of extending therapy for
ore than one year. Similarly, based on current data, we
ould not estimate the incremental value of each additional
onth of therapy and determine whether the cost-
ffectiveness of treatment varies during the 11 months of
rolonged treatment. More precise knowledge regarding the
uration of clinical effectiveness would allow the most
ost-effective regimen to be determined. Third, because of
he design of CREDO, we could not rule out the possibility
hat the preprocedural loading dose contributed to the
bserved effect of prolonged treatment. However, reaching
herapeutic levels earlier through loading reduces peripro-
edural events in the days after PCI, and a persistent loading
ffect beyond one month is unlikely. Fourth, unit costs were
ased on secondary sources. However, the results were
obust to variations in the cost of care. Fifth, outpatient
osts, non-health care costs of patients (e.g., travel, informal
are), and productivity losses were not available and were
xcluded from the analysis. Because the primary effect of
rolonged clopidogrel treatment was a reduction in MI and
xcluded costs associated with MI would be greater among
atients not receiving prolonged treatment, exclusion of
hese societal costs made our analysis more conservative
i.e., biased against prolonged treatment). Although bleed-
ng rates were slightly higher with prolonged treatment, the
esults were insensitive to variation in bleeding costs, and
xclusion of any outpatient or non-health care patient costs
ssociated with bleeds would not significantly affect results.
ixth, costs incurred during years of life gained due to the
ntervention were not included. The results did not change
ppreciably when estimates of these costs were included
ecause of the relatively small survival difference involved
nd the effect of discounting on future costs. Finally, the
tudy was based on data collected before the introduction of
rug-eluting stents. With drug-eluting stents, clopidogrel
herapy is typically recommended for three to six months
fter PCI (rather than for one month). This delays but does
ot avoid the issue of whether to extend clopidogrel therapy
or one year.
olicy implications. Prolonging clopidogrel treatment for
p to one year after PCI is as economically attractive from
he societal perspective as many other health care interven-
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igh-risk patients. However, without comprehensive med-
cation coverage, the cost of the therapy would be borne
rimarily by patients already facing significant medication
xpenses. The financial burden would be alleviated substan-
ially with a moderate reduction in the price of clopidogrel.
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